

# DEVELOPMENT OF AN INTERACTIVE PLATFORM FOR PROVINCE CLINICAL PHARMACEUTICS WHO ARE IN CHARGE OF THE TREATMENT OF HEPATITIS C INFECTED PATIENTS

S. Jornet Montaña<sup>1</sup>, M. Martín Marqués<sup>1</sup>, P. Jolonch Santasusagna<sup>2</sup>, M. Juan Aguilar<sup>3</sup>, C. Gomez Blanco<sup>2</sup>, P. Salvador Collado<sup>4</sup>.

<sup>1</sup>Hospital Universitari Joan XXIII, Pharmacy, Tarragona, Spain.

<sup>2</sup>Hospital Sant Pau i Santa Tecla, Pharmacy, Tarragona, Spain.

<sup>3</sup>Hospital Verge de la Cinta, Pharmacy, Tortosa, Spain.

<sup>4</sup>Hospital Sant Joan de Reus, Pharmacy, Reus, Spain.


Correspondence to Marta Martín Marqués: martamartin.hj23.ics@gencat.cat

## What was done?

- ✓ To create an online platform to make inquiries, resolve doubts and establish a shared database among clinical pharmacists within the province.

## Why was it done?

- ✓ The constant development of therapies against Hepatitis C and the lack of experience in their management require health professionals to work together.




## How was it done?



Meetings of the provincial pharmaceutical association

- ✓ To identify necessities jointly
- ✓ To determine the best communication system



## What has been achieved?

Pharmaceutical association creates



Interactive platform (virtual campus)

Sending inquiries and comments about side effects and interactions

Debate forums to answer questions, and promotes knowledge

Creation of drug interactions database

Written information (patient brochures, bibliography and scientific societies links)

- ✓ Knowing specific combinations of drugs have been used and which was the hospital's own experience, even if no official studies exist.
- ✓ Updating the previously introduced interactions and shows who has done it (this participant can be asked if it is necessary).



## What next?

- ✓ The equal treatment of all patients independently of the hospital where they are located.
- ✓ To work together for the same cause and overcome individual knowledge and resources constraints.

- ✓ It will be used for other illness for which a special pharmaceutical attention is required.
- ✓ It will be expanded by inviting other provinces.

## Acknowledgements

1. Hep-druginteractions.org. University of Liverpool. [cited 20-09-15]. Available at: <http://www.hepdruginteractions.org>  
2. Thomson Healthcare. Micromedex 2.0: Interactions of drugs. [cited 02-06-15]. Available at: <http://www.micromedexsolutions.com/home/dispatch>

No conflict of interest.

Hospital Pharmacists taking the lead –partnerships and technologies

21<sup>st</sup> Congress of EAHP  
16-18 March 2016, Vienna, Austria